Navigation Links
Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/24/2009

CARLSBAD, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Piper Jaffray's 21st Annual Health Care Conference on Tuesday, December 1, 2009, at 10:30 a.m. ET at The New York Palace Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... UNION CITY, Calif. , April 24, 2017 /PRNewswire/ ... providing durability, grip, protection, and comfort, announces the release ... the Powerform S8+. This most recent example of leading ... high density grip pattern for 200% more tactile grip ... in user protection and durability. With TracTek and a ...
(Date:4/21/2017)... -- Halo Labs announces the launch of a novel ... the Horizon at PEGS 2017 in Boston ... sub visible particulate matter in biopharmaceutical samples to enable ... as candidate selection and pre-formulation. Halo Labs ... Elion Labs for system validation. "We are ...
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... Women's Excellence specializes in pelvic conditions and has helped many women become ... Excellence uses a combination of office-based and simple outpatient evaluations. We can ...
(Date:4/26/2017)... ... ... RawTrition now brings you BioEnergy which is a powder capsule whole food ... RawTrition is taking nutrients to the next level! The superfoods in RawTrition's BioEnergy ... (unlike the synthetically made options that are on the market). , Founder of RawTrition, ...
(Date:4/26/2017)... ... 2017 , ... New SUPRO® XT55 Isolated Soy Protein ... helping beverage manufacturers more effectively manage protein costs. “Soy protein has always been ... as more stable pricing over time. Now it’s even more relevant as plant ...
(Date:4/26/2017)... ... 2017 , ... MYOLYN, a medical technology company dedicated to ... 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two of ... are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation (FES) ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
Breaking Medicine News(10 mins):